FDA commissioner
This article was originally published in The Tan Sheet
Executive Summary
White House health and economic advisor Mark McClellan, PhD/MD, sworn in as FDA commissioner Nov. 14. McClellan was unanimously confirmed by the Senate Oct. 17 (1"The Tan Sheet" Oct. 21, 2002, In Brief). During groundbreaking ceremony for new FDA facilities in White Oak, Md., McClellan delivered his first official speech as commissioner, stressing the importance of employee morale, recruitment and retention...
You may also be interested in...
FDA Commissioner McClellan
White House health and economic advisor Mark McClellan, MD/PhD, unanimously confirmed by Senate Oct. 17 after Health Committee member Jeff Bingaman (D-N.M.) lifted hold on nomination (1"The Tan Sheet" Oct. 14, 2002, p. 7). Confirmation comes 21 months after former Commissioner Jane Henney, MD, left office. Although no swearing-in date had been set as of Oct. 18, FDA's Science Board meeting in Rockville, Md. Oct. 25 could mark his first public appearance as commissioner. Meeting agenda lists introductory remarks to be given by McClellan "pending confirmation." Meeting will include discussion of CFSAN counterterrorism efforts, CDER's drug GMP initiative...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.